The inhibitory effect of betulinic acid on epithelial-mesenchymal transition pathway in renal cell carcinoma
Related Experiment Video
Updated: Sep 1, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Merve Nur Ataş1,2, Barış Ertuğrul1, Elif Sinem İplik3
1Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Abstract:
Renal cancer is the most lethal urological cancer and characterized by high metastasis rate at initial diagnosis and drug resistance to current chemotherapeutics. Betulinic acid is a pentacyclic triterpene with broad biological activity that occurs naturally in variety of plants. Even though the anti-cancer efficacy of betulinic acid have been reported by many studies, the information about the pathways and the molecules which are affected by betulinic acid in renal cancer are limited. Epithelial-mesenchymal transition (EMT) is considered as the initial step of metastasis and contributes to drug resistance of cancer cells. Depending on the role of EMT in cancer progression and drug resistance, targeting EMT may represent an effective strategy in this context. Therefore, we aimed to investigate the anti-metastatic effects of betulinic acid on renal cell carcinoma cells by evaluating two EMT markers, SNAIL-1, and SDC-2. Following the treatment of betulinic acid at determined doses by WST-1 cytotoxicity assay in our previous study, SDC-2 expression level was decreased in both cell lines. Additionally, in correlation with this result, we also found a reduction in SDC-2 and SNAIL-1 protein levels which are measured by ELISA. Furthermore, the migration and invasion capacities were suppressed by betulinic acid treatment in metastatic renal adenocarcinoma ACHN cells. Taken together, our findings indicate that betulinic acid may constitute a potential treatment approach for renal cancer with further investigations.
Insights
Betulinic acid shows promise in combating renal cancer metastasis and drug resistance by inhibiting epithelial-mesenchymal transition (EMT). This natural compound reduced key EMT markers and suppressed cancer cell migration and invasion.
Area of Science:
- Oncology
- Pharmacology
- Natural Products
Background:
- Renal cancer is a lethal malignancy with high metastasis and drug resistance.
- Betulinic acid, a plant-derived triterpene, exhibits anti-cancer properties, but its mechanisms in renal cancer are not fully understood.
- Epithelial-mesenchymal transition (EMT) drives metastasis and drug resistance in cancer.
Purpose of the Study:
- To investigate the anti-metastatic effects of betulinic acid on renal cell carcinoma.
- To evaluate the impact of betulinic acid on EMT markers, specifically SNAIL-1 and SDC-2.
- To assess the influence of betulinic acid on cancer cell migration and invasion.
Main Methods:
- Treatment of renal cell carcinoma cells with betulinic acid.
- WST-1 cytotoxicity assay to determine effective doses.
- ELISA to measure protein levels of SDC-2 and SNAIL-1.
- Assessment of cell migration and invasion capacities.
Main Results:
- Betulinic acid treatment decreased SDC-2 expression levels in renal cell carcinoma cell lines.
- A reduction in SDC-2 and SNAIL-1 protein levels was observed.
- Betulinic acid suppressed the migration and invasion capacities of metastatic renal adenocarcinoma ACHN cells.
Conclusions:
- Betulinic acid demonstrates anti-metastatic effects in renal cancer models.
- Targeting EMT pathways with betulinic acid may be a viable strategy for renal cancer treatment.
- Further research into betulinic acid as a potential renal cancer therapeutic is warranted.

